Physician profile
Nicole M Kuderer
NPI 1831357094
$38,903.25
in general payments reported to CMS, 2019-2025
13 companies · $7,922 in 2025
The $7,922 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,060 · 2020: $7,776 · 2021: $12K · 2022: $3,300 · 2023: $351 · 2024: $2,187 · 2025: $7,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,063 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,187 · Travel and Lodging: $2,176 · Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,062.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,186.50 |
| Travel and Lodging | $2,176.41 |
| Food and Beverage | $1,033.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $20,915.75 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,950.85 | 2019-2022 | |
| Spectrum Pharmaceuticals INC. | $4,568.14 | 2019 | |
| Seagen INC. | $2,190.00 | 2020 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Fresenius Kabi USA, LLC | $295.69 | 2023 | Stimufend |
| Dova Pharmaceuticals | $167.46 | 2019 | |
| Eli Lilly and Company | $83.96 | 2019 | |
| Secura Bio, INC. | $70.76 | 2019 | |
| Genentech USA, INC. | $61.45 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $55.28 | 2023 | |
| Lilly USA, LLC | $32.09 | 2019 | |
| Pfizer INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Kuderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.